Liptin 50mg Tab 10s

What it is used for: Diabetes.

Indications as listed by the manufacturer: Vildagliptin is indicated for the treatment of type 2 diabetes mellitus in adults:As monotherapy - In patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. As dual oral therapy in combination with - Metformin, in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with metformin.- Sulfonylurea, in patients with insufficient glycemic control despite maximal tolerated dose of a sulfonylurea and for whom metformin is inappropriate due to contraindications or intolerance.- Thiazolidinedione, in patients with insufficient glycemic control and for whom the use of a thiazolidinedione is appropriate. As triple oral therapy in combination with- Sulfonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycemic control. Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycemic control.

How it works: The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).

Active ingredient: Vildagliptin.

Reported side effects: Monotherapy Common: Dizziness. Uncommon: Hypoglycemia, headache, edema peripheral, constipation & arthralgia. Very Rare: Upper respiratory tract infection & nasopharyngitis. Combination with Metformin Common: Hypoglycemia, tremor, headache, dizziness & nausea. Uncommon: Fatigue. Combination with Sulfonylurea Common: Hypoglycemia, tremor, headache, dizziness & asthenia. Uncommon: Constipation. Very Rare: Nasopharyngitis. Combination with Thiazolidinedione Common: Weight increase & edema peripheral. Uncommon: Hypoglycemia, headache & asthenia. Combination with Metformin and Sulfonylurea Common: Hypoglycemia, dizziness, tremor, hyperhidrosis & asthenia. Combination with Insulin Common: Decreased blood glucose, headache, chills, nausea, gastroesophageal reflux disease. Uncommon: Diarrhea & flatulence.

Known drug interactions: Vildagliptin has a low potential for interactions with co-administered medicinal products. Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP450 enzymes, it isnot likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes. As with other oral antidiabetic medicinal products the hypoglycemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.

When used as monotherapy, in combination with metformin, in combination with thiazolidinedione, in combination with metformin and a sulfonylurea, or in combination with insulin (with or without metformin), the recommended daily dose of Vildagliptin is 100mg, administered as one dose of 50mg in the morning and one dose of 50mg in the evening. When used in dual combination with a sulfonylurea, the recommended dose of Vildagliptin is 50mg once daily administered in the morning. If a dose of Vildagliptin is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.

Active ingredient: Vildagliptin. Labelled strength: 50mg.

Store this medicine at room temperature, away from direct light and heat.

Manufactured by Liptin Laboratories (Pvt) Ltd.. Country of origin: Pakistan.